The genomic heritage of lymph node metastases: Implications for clinical management of patients with breast cancer

被引:26
作者
Becker, Tyson E. [1 ]
Ellsworth, Rachel E. [1 ,2 ]
Deyarmin, Brenda [1 ]
Patney, Heather L. [1 ]
Jordan, Rick M. [1 ]
Hooke, Jeffrey A. [3 ]
Shriver, Craig D. [3 ]
Ellsworth, Darrell L. [1 ]
机构
[1] Windber Res Inst, Clin Breast Care Project, Windber, PA 15963 USA
[2] Henry M Jackson Fdn, Adv Mil Med, Rockville, MD 20852 USA
[3] Walter Reed Army Med Ctr, Clin Breast Care Project, Washington, DC 20307 USA
关键词
metastasis; breast cancer; allelic imbalance; axillary lymph nodes;
D O I
10.1245/s10434-008-9815-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Metastatic breast cancer is an aggressive disease associated with recurrence and decreased survival. To improve outcomes and develop more effective treatment strategies for patients with breast cancer, it is important to understand the molecular mechanisms underlying metastasis. Methods: We used allelic imbalance (AI) to determine the molecular heritage of primary breast tumors and corresponding metastases to the axillary lymph nodes. Paraffin-embedded samples from primary breast tumors and matched metastases (n = 146) were collected from 26 patients with node-positive breast cancer involving multiple axillary nodes. Hierarchical clustering was used to assess overall differences in the patterns of AI, and phylogenetic analysis inferred the molecular heritage of axillary lymph node metastases. Results: Overall frequencies of AI were significantly higher (P < 0.01) in primary breast tumors (23%) than in lymph node metastases (15%), and there was a high degree of discordance in patterns of AI between primary breast carcinomas and the metastases. Metastatic tumors in the axillary nodes showed different patterns of chromosomal changes, suggesting that multiple molecular mechanisms may govern the process of metastasis in individual patients. Some metastases progressed with few genomic alterations, while others harbored many chromosomal alterations present in the primary tumor. Conclusions: The extent of genomic heterogeneity in axillary lymph node metastases differs markedly among individual patients. Genomic diversity may be associated with response to adjuvant therapy, recurrence, and survival, and thus may be important in improving clinical management of breast cancer patients.
引用
收藏
页码:1056 / 1063
页数:8
相关论文
共 40 条
[1]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[2]  
[Anonymous], SEER CANC STAT REV
[3]  
[Anonymous], 1989, Cladistics, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X
[4]   Management of the axilla in women with breast cancer [J].
Benson, John R. ;
della Rovere, G. Querci .
LANCET ONCOLOGY, 2007, 8 (04) :331-348
[5]   Metastasis genes: A progression puzzle [J].
Bernards, R ;
Weinberg, RA .
NATURE, 2002, 418 (6900) :823-823
[6]   Allelic loss detection in inflammatory breast cancer:: Improvement with laser microdissection [J].
Bertheau, P ;
Plassa, LF ;
Lerebours, F ;
de Roquancourt, A ;
Turpin, E ;
Lidereau, R ;
de Thé, H ;
Janin, A .
LABORATORY INVESTIGATION, 2001, 81 (10) :1397-1402
[7]   A METHOD FOR DEDUCING BRANCHING SEQUENCES IN PHYLOGENY [J].
CAMIN, JH ;
SOKAL, RR .
EVOLUTION, 1965, 19 (03) :311-326
[8]   Genetic and epigenetic alterations in sentinel lymph nodes metastatic lesions compared to their corresponding primary breast tumors [J].
Cavalli, LR ;
Urban, CA ;
Dai, DQ ;
de Assis, S ;
Tavares, DC ;
Rone, JD ;
Bleggi-Torres, LF ;
Lima, RS ;
Cavalli, IJ ;
Issa, JPJ ;
Haddad, BR .
CANCER GENETICS AND CYTOGENETICS, 2003, 146 (01) :33-40
[9]   Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process [J].
Demicheli, R ;
Miceli, R ;
Moliterni, A ;
Zambetti, M ;
Hrushesky, WJM ;
Retsky, MW ;
Valagussa, P ;
Bonadonna, G .
ANNALS OF ONCOLOGY, 2005, 16 (09) :1449-1457
[10]  
Eifel P, 2001, JNCI-J NATL CANCER I, V93, P979